Name | Number of supported studies | Average coverage | |
---|---|---|---|
type I pneumocyte | 3 studies | 24% ± 4% |
Insufficient scRNA-seq data for expression of TENT5B at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 99% | 9001.80 | 1431 / 1445 | 70% | 27.45 | 129 / 183 |
skin | 83% | 8536.42 | 1504 / 1809 | 86% | 29.11 | 407 / 472 |
breast | 61% | 1788.09 | 282 / 459 | 89% | 28.39 | 992 / 1118 |
uterus | 60% | 1959.95 | 102 / 170 | 83% | 41.46 | 381 / 459 |
prostate | 49% | 1234.83 | 119 / 245 | 75% | 10.70 | 378 / 502 |
lung | 59% | 1331.04 | 339 / 578 | 64% | 10.32 | 736 / 1155 |
bladder | 76% | 3895.62 | 16 / 21 | 39% | 8.28 | 197 / 504 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.21 | 1 / 1 |
blood vessel | 96% | 5483.16 | 1286 / 1335 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 89% | 44.95 | 40 / 45 |
intestine | 67% | 2926.69 | 644 / 966 | 19% | 3.17 | 102 / 527 |
ovary | 11% | 251.76 | 19 / 180 | 66% | 8.17 | 285 / 430 |
thymus | 16% | 236.11 | 105 / 653 | 59% | 6.09 | 355 / 605 |
heart | 69% | 1750.33 | 593 / 861 | 0% | 0 | 0 / 0 |
stomach | 38% | 1495.13 | 135 / 359 | 28% | 4.06 | 80 / 286 |
pancreas | 0% | 0 | 0 / 328 | 42% | 3.71 | 75 / 178 |
kidney | 15% | 160.81 | 13 / 89 | 25% | 2.90 | 229 / 901 |
adipose | 29% | 490.31 | 345 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 25% | 1.63 | 20 / 80 |
brain | 0% | 1.26 | 3 / 2642 | 25% | 3.33 | 175 / 705 |
adrenal gland | 0% | 0 | 0 / 258 | 12% | 1.45 | 28 / 230 |
liver | 0% | 0 | 0 / 226 | 3% | 0.30 | 14 / 406 |
muscle | 0% | 6.99 | 4 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
peripheral blood | 0% | 0 | 0 / 929 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spleen | 0% | 0 | 0 / 241 | 0% | 0 | 0 / 0 |
GO_0008285 | Biological process | negative regulation of cell population proliferation |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0048255 | Biological process | mRNA stabilization |
GO_0045786 | Biological process | negative regulation of cell cycle |
GO_0045727 | Biological process | positive regulation of translation |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_1990817 | Molecular function | poly(A) RNA polymerase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TENT5B |
Protein name | Terminal nucleotidyltransferase 5B (EC 2.7.7.19) (Non-canonical poly(A) polymerase FAM46B) |
Synonyms | FAM46B |
Description | FUNCTION: Catalyzes the transfer of one adenosine molecule from an ATP to an mRNA poly(A) tail bearing a 3'-OH terminal group in an ATP hydrolysis-dependent manner . May be involved in maintaining the translation efficiency of at least some genes through preventing degradation of their mRNAs . Prefers RNA molecules that are adenosine-rich close to 3'-end . In addition, may inhibit cell proliferation and cell cycle progression through ubiquitination of beta-catenin/CTNNB1 . . |
Accessions | ENST00000289166.6 Q96A09 |